BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19208794)

  • 21. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
    Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
    Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
    Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
    Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers to the enrollment of children in the Children's Oncology Group study of very low risk Wilms tumor: a report from the Children's Oncology Group.
    Fernandez CV; Li N; Mullen EA; Grundy PE; Perman EJ; Shamberger RC; Ehrlich PF; Dome JS
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):521-3. PubMed ID: 21941145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies.
    Reinhard H; Schmidt A; Furtwängler R; Leuschner I; Rübe C; Von Schweinitz D; Zoubek A; Niggli F; Graf N
    Oncol Rep; 2008 Aug; 20(2):463-7. PubMed ID: 18636212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ploidy changes between diagnosis and relapse in childhood renal tumours.
    O'Meara A; Gururangan S; Ball R; Kay E; Kelsey A
    Urol Res; 1993; 21(5):345-7. PubMed ID: 8279091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
    Sredni ST; Gadd S; Huang CC; Breslow N; Grundy P; Green DM; Dome JS; Shamberger RC; Beckwith JB; Perlman EJ;
    Clin Cancer Res; 2009 Nov; 15(22):6800-9. PubMed ID: 19903788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased microvascular density predicts relapse in Wilms' tumor.
    Abramson LP; Grundy PE; Rademaker AW; Helenowski I; Cornwell M; Katzenstein HM; Reynolds M; Arensman RM; Crawford SE
    J Pediatr Surg; 2003 Mar; 38(3):325-30; discussion 325-30. PubMed ID: 12632343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
    Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
    Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
    Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
    J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting.
    Brok J; Mavinkurve-Groothuis AMC; Drost J; Perotti D; Geller JI; Walz AL; Geoerger B; Pasqualini C; Verschuur A; Polanco A; Jones KP; van den Heuvel-Eibrink M; Graf N; Spreafico F
    Eur J Cancer; 2021 Feb; 144():113-122. PubMed ID: 33341445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors responsible for stage III disease in patients with Wilms tumor enrolled in the JWiTS-2 study.
    Oue T; Fukumoto K; Souzaki R; Takimoto T; Koshinaga T;
    Pediatr Surg Int; 2019 Oct; 35(10):1095-1099. PubMed ID: 31396736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms' tumor: a 10 year retrospective study.
    Seyed-Ahadi MM; Khaleghnejad-Tabari A; Mirshemirani A; Sadeghian N; Amonollahi O
    Arch Iran Med; 2007 Jan; 10(1):65-9. PubMed ID: 17198457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.
    Shamberger RC; Guthrie KA; Ritchey ML; Haase GM; Takashima J; Beckwith JB; D'Angio GJ; Green DM; Breslow NE
    Ann Surg; 1999 Feb; 229(2):292-7. PubMed ID: 10024113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters.
    Zirn B; Hartmann O; Samans B; Krause M; Wittmann S; Mertens F; Graf N; Eilers M; Gessler M
    Int J Cancer; 2006 Apr; 118(8):1954-62. PubMed ID: 16287080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk stratification for wilms tumor: current approach and future directions.
    Dome JS; Perlman EJ; Graf N
    Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wilms' tumor: long-term results from a single institution.
    Zaghloul MS; Hussein MH; el Koutbey M
    J Surg Oncol; 1994 May; 56(1):25-31. PubMed ID: 8176938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wilms Tumor: Challenges and Newcomers in Prognosis.
    Parsons LN
    Surg Pathol Clin; 2020 Dec; 13(4):683-693. PubMed ID: 33183727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation Potential of Hypodifferentiated Subsets of Nephrogenic Rests and Its Relationship to Prognosis in Wilms Tumor.
    Liu M; Lu J; Yu C; Zhao J; Wang L; Hu Y; Chen L; Han R; Liu Y; Sun M; Wei G; Wu S
    Fetal Pediatr Pathol; 2024; 43(2):123-139. PubMed ID: 38217324
    [No Abstract]   [Full Text] [Related]  

  • 40. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
    Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
    Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.